Evidence map›Paper›PMID 38854737›Full record

ArticleFrontiers in oncology2024

Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of

Evan DuBose, Samantha M Bevill, Dana K Mitchell, Noah Sciaky, Brian T Golitz, Shelley A H Dixon, Steven D Rhodes, James E Bear, Gary L Johnson, Steven P Angus

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Proteomic approaches for interrogating kinase signaling networks.The Journal of investigative dermatology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Evan DuBose *Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
Samantha M Bevill *Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
Dana K MitchellDepartment of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States.
Noah SciakyDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
Brian T GolitzDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
Shelley A H DixonDepartment of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States.
Steven D RhodesDepartment of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, United States.
James E BearDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
Gary L JohnsonDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.
Steven P AngusDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC, United States.

Funding

Systematic Analysis of the Actin Cytoskeleton and Directed Cell MigrationR35GM130312 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI JAMES E BEAR · 2019 to 2026
$4.8M
NIGMS NIH HHS R35 GM130312
6 · The paper itself

Abstract

Introduction: Approximately 50% of melanomas harbor an activating Methods: To compare the response of Results: RNA sequencing and functional kinome analysis revealed that the loss of PTEN led to an induction of Conclusions: The findings indicate that

Indexed as

drug synergyERBB3kinase inhibitormelanomaresistance

Identifiers

PMID38854737
PMCPMC11159048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.